Venous thromboembolism (VTE) is the third most common cause of death worldwide. The
incidence of VTE varies according to different countries, ranging from 1–2 per 1000 person …

In August 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

Men are consistently overrepresented in severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection, and coronavirus disease 2019 (COVID-19) severe outcomes …

Background We update recommendations on 12 topics that were in the 9th edition of these
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …

Objectives To determine the rate of a first recurrent venous thromboembolism (VTE) event
after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked …

Background: The long-term risk for major bleeding in patients receiving extended (beyond
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

The task of developing ESC Guidelines covers not only the integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …

Introduction D‐dimer assay, generally evaluated according to cutoff points calibrated for VTE
exclusion, is used to estimate the individual risk of recurrence after a first idiopathic event of …

Venous thromboembolism (VTE) is the third most common cardiovascular disorder, affecting
up to 5% of the population. VTE commonly manifests as lower-extremity deep venous …